九典制药(300705) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company reached ¥22,364,024.43, an increase of 139.54% year-on-year[9]. - Operating income for the reporting period was ¥263,531,787.85, reflecting a growth of 12.94% compared to the same period last year[9]. - Basic earnings per share were ¥0.10, representing a 150.00% increase compared to the same period last year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,841,146.66, an increase of 98.19% year-on-year[9]. - The company reported a net profit increase, with retained earnings rising from CNY 213,817,633.47 to CNY 260,555,179.97, an increase of approximately 22%[42]. - The net profit for the current period is CNY 25,657,091.12, compared to CNY 14,068,283.43 in the previous period, indicating a significant increase of approximately 82.5%[62]. - The total comprehensive income attributable to the parent company's owners is CNY 22,364,024.43, significantly higher than CNY 9,336,294.52 in the previous period, indicating an increase of approximately 139.5%[61]. - The company reported a total comprehensive income of CNY 51,875,888.05, an increase from CNY 48,051,606.23, indicating a growth of about 5.9%[79]. Cash Flow - The net cash flow from operating activities was ¥45,833,072.05, a significant increase of 617.56% year-on-year[9]. - Net cash flow from operating activities surged by 2,355.87% to ¥96,365,368.27 from ¥3,923,876.69, attributed to increased government subsidies received and reduced payments for goods[20]. - Cash inflow from operating activities totaled CNY 725,617,335.80, compared to CNY 674,753,601.34 in the previous period, indicating an increase of about 7.5%[82]. - The net cash flow from operating activities was CNY 96,365,368.27, significantly higher than CNY 3,923,876.69 in the previous period, showing a substantial improvement[82]. - Cash inflow from financing activities was CNY 9,500,000.00, a decrease from CNY 85,000,000.00 in the previous period, indicating a decline of approximately 88.8%[85]. - The net cash flow from financing activities was -CNY 72,651,373.62, compared to CNY 33,065,978.46 in the previous period, reflecting a negative shift[85]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,055,530,066.32, a decrease of 1.55% compared to the end of the previous year[9]. - Current liabilities decreased significantly from CNY 200,543,702.32 to CNY 130,068,196.04, a reduction of about 35%[39]. - Non-current liabilities increased from CNY 109,684,391.04 to CNY 116,853,397.66, representing a rise of approximately 6.5%[39]. - The total equity attributable to shareholders rose from CNY 761,870,926.12 to CNY 808,608,472.62, an increase of about 6.1%[42]. - The company's total liabilities decreased from CNY 310,228,093.36 to CNY 246,921,593.70, a reduction of approximately 20.4%[39]. - Total liabilities reached $150.52 million, with current liabilities at $145.55 million and non-current liabilities at $4.97 million[107]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,617[13]. - The largest shareholder, Zhu Zhihong, held 37.16% of the shares, totaling 87,210,000 shares[13]. Operational Costs and Expenses - The total operating costs for the current period are CNY 243,128,400.83, compared to CNY 217,018,501.83 in the previous period, which is an increase of approximately 12.1%[52]. - The company's sales expenses have risen to CNY 138,020,268.69 from CNY 102,851,251.44, marking an increase of approximately 34.0%[59]. - Research and development expenses for the current period amount to CNY 19,254,954.20, down from CNY 24,115,268.35 in the previous period, reflecting a decrease of about 20.2%[59]. - Financial expenses increased by 46.88% to ¥3,757,618.18 from ¥2,558,368.14 due to higher borrowing interest[20]. Future Plans - The company plans to issue convertible bonds to unspecified objects, with the proposal approved by the board and shareholders[23][24]. - The company plans to continue focusing on market expansion and new product development strategies in the upcoming quarters[66]. Compliance and Standards - The company has no violations regarding external guarantees or non-operating fund occupation during the reporting period[25][26]. - The company has implemented new revenue and leasing standards starting from 2020, affecting financial reporting[92].